Olpadronic acid | CAS#63132-39-8 | biochemical

MedKoo Cat#: 591472 | Name: Olpadronic acid

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Olpadronic acid is a biochemical.

Chemical Structure

Olpadronic acid

CAS#63132-39-8

Theoretical Analysis

MedKoo Cat#: 591472

Name: Olpadronic acid

CAS#: 63132-39-8

Chemical Formula: C5H15NO7P2

Exact Mass: 263.0324

Molecular Weight: 263.12

Elemental Analysis: C, 22.82; H, 5.75; N, 5.32; O, 42.56; P, 23.54

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 410.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Me2-APD; Me2 APD; Me2APD;

IUPAC/Chemical Name

Phosphonic acid, (3-(dimethylamino)-1-hydroxypropylidene)bis-

InChi Key

UGEPSJNLORCRBO-UHFFFAOYSA-N

InChi Code

InChI=1S/C5H15NO7P2/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13)

SMILES Code

OC(P(O)(O)=O)(P(O)(O)=O)CCN(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Olpadronic acid is a biochemical.

In vitro activity:

TBD

In vivo activity:

TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 263.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Roldán EJ. [Pamidronate and olpadronate discoverer, Prof. Olav Maria Leonard Bijvoet passed away]. Medicina (B Aires). 2014;74(5):425-7. Spanish. PubMed PMID: 25347910. 2: Capozza RF, Mondelo N, Reina PS, Nocciolino L, Meta M, Roldan EJ, Ferretti JL, Cointry GR. Mineralization- and remodeling-unrelated improvement of the post-yield properties of rat cortical bone by high doses of olpadronate. J Musculoskelet Neuronal Interact. 2013 Jun;13(2):185-94. PubMed PMID: 23728105. 3: Morelli S, Bilbao PS, Katz S, Lezcano V, Roldán E, Boland R, Santillan G. Protein phosphatases: possible bisphosphonate binding sites mediating stimulation of osteoblast proliferation. Arch Biochem Biophys. 2011 Mar 15;507(2):248-53. doi: 10.1016/j.abb.2010.12.013. Epub 2010 Dec 15. PubMed PMID: 21167123. 4: Kuijpers SC, de Jong E, Hamdy NA, van Merkesteyn JP. Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates. J Craniomaxillofac Surg. 2011 Jan;39(1):65-8. doi: 10.1016/j.jcms.2010.03.014. Epub 2010 Apr 27. PubMed PMID: 20427193. 5: Bigi MM, Escudero ND, Ubios AM, Mandalunis PM. Evaluation of vascular endothelial growth factor (VEGF) in interradicular bone marrow in olpadronate treated animals. Acta Odontol Latinoam. 2010;23(3):265-9. PubMed PMID: 21638970. 6: Escudero ND, Lacave M, Ubios AM, Mandalunis PM. Effect of monosodium olpadronate on osteoclasts and megakaryocytes: an in vivo study. J Musculoskelet Neuronal Interact. 2009 Apr-Jun;9(2):109-20. PubMed PMID: 19516086. 7: Pellegrini GG, Gonzales CM, Somoza JC, Friedman SM, Zeni SN. Correlation between salivary and serum markers of bone turnover in osteopenic rats. J Periodontol. 2008 Jan;79(1):158-65. doi: 10.1902/jop.2008.070168 . PubMed PMID: 18166106. 8: Weissglas M, Löwik C, Schamhart D, Theuns H, Kurth KH, Papapoulos S. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate. BJU Int. 2007 Jun;99(6):1530-3. Epub 2007 Apr 8. PubMed PMID: 17428243. 9: Kok DH, Sakkers RJ, Janse AJ, Pruijs HE, Verbout AJ, Castelein RM, Engelbert RH. Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. Eur J Pediatr. 2007 Nov;166(11):1155-61. Epub 2007 Feb 17. PubMed PMID: 17308899. 10: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851. 11: Yang M, Burton DW, Geller J, Hillegonds DJ, Hastings RH, Deftos LJ, Hoffman RM. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clin Cancer Res. 2006 Apr 15;12(8):2602-6. PubMed PMID: 16638872. 12: Goya JA, Paez HA, Mandalunis PM. Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats. J Periodontol. 2006 Jan;77(1):1-6. PubMed PMID: 16579696. 13: Twiss IM, van den Berk AH, de Kam ML, Bosch JJ, Cohen AF, Vermeij P, Burggraaf J. A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans. J Clin Pharmacol. 2006 Apr;46(4):483-7. PubMed PMID: 16554458. 14: Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact. 2005 Jun;5(2):174-81. PubMed PMID: 15951635. 15: Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004 May 1;363(9419):1427-31. PubMed PMID: 15121405. 16: Eekhoff ME, Zwinderman AH, Haverkort DM, Cremers SC, Hamdy NA, Papapoulos SE. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone. 2003 Nov;33(5):831-8. PubMed PMID: 14623059. 17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506. PubMed PMID: 12949633. 18: Cremers SC, Eekhoff ME, Den Hartigh J, Hamdy NA, Vermeij P, Papapoulos SE. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res. 2003 May;18(5):868-75. PubMed PMID: 12733726. 19: Vazquez G, Santillan G, Boland R, Roldán E, Pérez-Lloret A. Modulation of cytosolic calcium levels in osteoblast-like osteosarcoma cells by olpadronate and its amino-derivative IG-9402. Calcif Tissue Int. 2003 Mar;72(3):215-21. Epub 2002 Dec 10. PubMed PMID: 12469251. 20: Soerdjbalie-Maikoe V, Pelger RC, Lycklama à Nijeholt GA, Arndt JW, Zwinderman AH, Papapoulos SE, Hamdy NA. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):494-8. Epub 2002 Feb 15. PubMed PMID: 11914887.